Previous Close | 1.0200 |
Open | N/A |
Bid | 0.2000 |
Ask | 0.4500 |
Strike | 13.00 |
Expire Date | 2024-08-16 |
Day's Range | 1.0200 - 1.0200 |
Contract Range | N/A |
Volume | |
Open Interest | 2 |
Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in revenue cycle management.
Explore key insights from Myriad Genetics' Q1 2024 earnings, featuring significant revenue increases and strategic initiatives aimed at enhancing market position.
While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.